Identification of Antibiotics That Diminish Disease in a Murine Model of Enterohemorrhagic Escherichia coli Infection.
Sabrina MühlenIsabell RammingMarina C PilsMartin KoeppelJana GlaserJohn LeongAntje FliegerBärbel StecherPetra DerschPublished in: Antimicrobial agents and chemotherapy (2020)
Infections with enterohemorrhagic Escherichia coli (EHEC) cause disease ranging from mild diarrhea to hemolytic-uremic syndrome (HUS) and are the most common cause of renal failure in children in high-income countries. The severity of the disease derives from the release of Shiga toxins (Stx). The use of antibiotics to treat EHEC infections is generally avoided, as it can result in increased stx expression. Here, we systematically tested different classes of antibiotics and found that their influence on stx expression and release varies significantly. We assessed a selection of these antibiotics in vivo using the Citrobacter rodentium ϕstx 2dact mouse model and show that stx 2d-inducing antibiotics resulted in weight loss and kidney damage despite clearance of the infection. However, several non-Stx-inducing antibiotics cleared bacterial infection without causing Stx-mediated pathology. Our results suggest that these antibiotics might be useful in the treatment of EHEC-infected human patients and decrease the risk of HUS development.
Keyphrases
- escherichia coli
- weight loss
- mouse model
- poor prognosis
- endothelial cells
- young adults
- ejection fraction
- end stage renal disease
- type diabetes
- mental health
- bariatric surgery
- oxidative stress
- prognostic factors
- long non coding rna
- klebsiella pneumoniae
- biofilm formation
- binding protein
- staphylococcus aureus
- combination therapy
- pseudomonas aeruginosa
- patient reported outcomes
- roux en y gastric bypass
- candida albicans
- irritable bowel syndrome